Medication stops the attack, but physical therapy rebuilds the strength. Learn how specialized neuro-PT helps ‘re-map’ ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...

Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the ...

KYOTO, Japan — Subcutaneous (SC) immunoglobulin offers several benefits compared with intravenous (IV) infusion as maintenance treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), ...

Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% ...